COMPASS FINANCIAL MANAGEMENT LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

COMPASS FINANCIAL MANAGEMENT LLC’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.9K	Buy	+102	New	+$45.2K	0.01%	698

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

COMPASS FINANCIAL MANAGEMENT LLC's VRTX Position: Q2 2026 in Review

COMPASS FINANCIAL MANAGEMENT LLC opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 102 shares worth $48.9K. The stake represents 0.01% of the portfolio and ranks #698 among its holdings.

1,406 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

COMPASS FINANCIAL MANAGEMENT LLC held 102 shares of Vertex Pharmaceuticals worth $48.9K as of Q2 2026.
Vertex Pharmaceuticals was a new COMPASS FINANCIAL MANAGEMENT LLC position in Q2 2026.
Vertex Pharmaceuticals made up 0.01% of COMPASS FINANCIAL MANAGEMENT LLC's portfolio in Q2 2026, its #698 holding.
1,406 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on COMPASS FINANCIAL MANAGEMENT LLC's 13F filing for Q2 2026, filed 12 Aug 2026.